Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: A single institution experience

Martin H. Voss, Matthew A. Lunning, Jocelyn C. Maragulia, Esperanza B. Papadopoulos, Jenna Goldberg, Andrew D. Zelenetz, Steven M. Horwitz

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Introduction: Hepatosplenic T-cell lymphoma is a rare form of extranodal non-Hodgkin lymphoma, first recognized as a distinct entity in the Revised European-American Lymphoma classification. Typical presentation includes lymphomatous infiltration of spleen and liver, and peripheral lymphadenopathy is rarely seen. The prognosis is almost uniformly poor, and there are no prospective studies of treatment of HSTCL. Patients and Methods: For this report, we conducted a retrospective review of all pts who underwent treatment for HSTCL at our institution. Individual chart review was performed to report clinical presentation, management, and outcome. Results: We identified 14 pts with HSTCL managed at our center, 7 of which remain alive with median follow-up of 65.6 months. Six of 7 received alternative induction chemotherapy regimens such as ICE (ifosfamide, carboplatin, etoposide) or IVAC (ifosfamide, etoposide, high-dose cytarabine) as opposed to CHOP and all surviving pts had proceeded to undergo either autologous or allogeneic SCT. Conclusion: Our results suggest that use of non-CHOP induction regimen and early use of high dose therapy and SCT consolidation may translate to improved survival for pts with HSTCL.

Original languageEnglish (US)
Pages (from-to)8-14
Number of pages7
JournalClinical Lymphoma, Myeloma and Leukemia
Volume13
Issue number1
DOIs
StatePublished - Feb 1 2013

Fingerprint

Induction Chemotherapy
T-Cell Lymphoma
Hematopoietic Stem Cell Transplantation
Ifosfamide
Etoposide
Carboplatin
Cytarabine
Non-Hodgkin's Lymphoma
Lymphoma
Therapeutics
Spleen
Prospective Studies
Survival
Liver

Keywords

  • Peripheral
  • TCR gamma-delta

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma : A single institution experience. / Voss, Martin H.; Lunning, Matthew A.; Maragulia, Jocelyn C.; Papadopoulos, Esperanza B.; Goldberg, Jenna; Zelenetz, Andrew D.; Horwitz, Steven M.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, No. 1, 01.02.2013, p. 8-14.

Research output: Contribution to journalArticle

@article{37dc6852f2024a9bb08d49cd3bbb7868,
title = "Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: A single institution experience",
abstract = "Introduction: Hepatosplenic T-cell lymphoma is a rare form of extranodal non-Hodgkin lymphoma, first recognized as a distinct entity in the Revised European-American Lymphoma classification. Typical presentation includes lymphomatous infiltration of spleen and liver, and peripheral lymphadenopathy is rarely seen. The prognosis is almost uniformly poor, and there are no prospective studies of treatment of HSTCL. Patients and Methods: For this report, we conducted a retrospective review of all pts who underwent treatment for HSTCL at our institution. Individual chart review was performed to report clinical presentation, management, and outcome. Results: We identified 14 pts with HSTCL managed at our center, 7 of which remain alive with median follow-up of 65.6 months. Six of 7 received alternative induction chemotherapy regimens such as ICE (ifosfamide, carboplatin, etoposide) or IVAC (ifosfamide, etoposide, high-dose cytarabine) as opposed to CHOP and all surviving pts had proceeded to undergo either autologous or allogeneic SCT. Conclusion: Our results suggest that use of non-CHOP induction regimen and early use of high dose therapy and SCT consolidation may translate to improved survival for pts with HSTCL.",
keywords = "Peripheral, TCR gamma-delta",
author = "Voss, {Martin H.} and Lunning, {Matthew A.} and Maragulia, {Jocelyn C.} and Papadopoulos, {Esperanza B.} and Jenna Goldberg and Zelenetz, {Andrew D.} and Horwitz, {Steven M.}",
year = "2013",
month = "2",
day = "1",
doi = "10.1016/j.clml.2012.09.002",
language = "English (US)",
volume = "13",
pages = "8--14",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "1",

}

TY - JOUR

T1 - Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma

T2 - A single institution experience

AU - Voss, Martin H.

AU - Lunning, Matthew A.

AU - Maragulia, Jocelyn C.

AU - Papadopoulos, Esperanza B.

AU - Goldberg, Jenna

AU - Zelenetz, Andrew D.

AU - Horwitz, Steven M.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Introduction: Hepatosplenic T-cell lymphoma is a rare form of extranodal non-Hodgkin lymphoma, first recognized as a distinct entity in the Revised European-American Lymphoma classification. Typical presentation includes lymphomatous infiltration of spleen and liver, and peripheral lymphadenopathy is rarely seen. The prognosis is almost uniformly poor, and there are no prospective studies of treatment of HSTCL. Patients and Methods: For this report, we conducted a retrospective review of all pts who underwent treatment for HSTCL at our institution. Individual chart review was performed to report clinical presentation, management, and outcome. Results: We identified 14 pts with HSTCL managed at our center, 7 of which remain alive with median follow-up of 65.6 months. Six of 7 received alternative induction chemotherapy regimens such as ICE (ifosfamide, carboplatin, etoposide) or IVAC (ifosfamide, etoposide, high-dose cytarabine) as opposed to CHOP and all surviving pts had proceeded to undergo either autologous or allogeneic SCT. Conclusion: Our results suggest that use of non-CHOP induction regimen and early use of high dose therapy and SCT consolidation may translate to improved survival for pts with HSTCL.

AB - Introduction: Hepatosplenic T-cell lymphoma is a rare form of extranodal non-Hodgkin lymphoma, first recognized as a distinct entity in the Revised European-American Lymphoma classification. Typical presentation includes lymphomatous infiltration of spleen and liver, and peripheral lymphadenopathy is rarely seen. The prognosis is almost uniformly poor, and there are no prospective studies of treatment of HSTCL. Patients and Methods: For this report, we conducted a retrospective review of all pts who underwent treatment for HSTCL at our institution. Individual chart review was performed to report clinical presentation, management, and outcome. Results: We identified 14 pts with HSTCL managed at our center, 7 of which remain alive with median follow-up of 65.6 months. Six of 7 received alternative induction chemotherapy regimens such as ICE (ifosfamide, carboplatin, etoposide) or IVAC (ifosfamide, etoposide, high-dose cytarabine) as opposed to CHOP and all surviving pts had proceeded to undergo either autologous or allogeneic SCT. Conclusion: Our results suggest that use of non-CHOP induction regimen and early use of high dose therapy and SCT consolidation may translate to improved survival for pts with HSTCL.

KW - Peripheral

KW - TCR gamma-delta

UR - http://www.scopus.com/inward/record.url?scp=84873311535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873311535&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2012.09.002

DO - 10.1016/j.clml.2012.09.002

M3 - Article

C2 - 23107915

AN - SCOPUS:84873311535

VL - 13

SP - 8

EP - 14

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 1

ER -